Search / Trial NCT06615024

Screening of Coexistence Between Sickle Cell Anaemia and G6PD Deficiency

Launched by FATMA HUSSEIN MAHMOUD · Sep 24, 2024

Trial Information

Current as of October 07, 2024

Not yet recruiting

Keywords

Description

Sickle cell disease (SCD) is not frequent in Egypt except in the Oases where the carrier rate varies from 9 to 22%. It is a hereditary blood disorder characterized by the production of abnormal hemoglobin molecules that cause red blood cells to take on a crescent or sickle shape. This haemoglobin called haemoglobin S, which causes red blood cells to become stiff and sticky, leading to various health complications as recurrent pain, fatigue, anaemia, and increased infection susceptibility.prevalence of G6PD deficiency is 4.3% with a male:female ratio of 3.2:1. Enzyme activity was significant...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • - All new born with good general health
  • Exclusion Criteria:
  • * 1-new born with high reticulocytic count 2-new born with bad general health

About Fatma Hussein Mahmoud

Fatma Hussein Mahmoud is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, she leads initiatives that prioritize ethical standards, scientific integrity, and regulatory compliance. Her extensive experience in clinical trial management encompasses protocol development, patient recruitment, and data analysis, ensuring that each study adheres to the highest quality standards. By fostering collaboration among multidisciplinary teams, Fatma strives to accelerate the translation of research findings into effective treatments, ultimately contributing to the enhancement of healthcare practices.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0